These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33753855)

  • 1. A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma.
    Mei Y; Chen MM; Liang H; Ma L
    Commun Biol; 2021 Mar; 4(1):383. PubMed ID: 33753855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 4. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
    Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
    Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma.
    Qu Y; Zhang S; Zhang Y; Feng X; Wang F
    Virchows Arch; 2021 May; 478(5):943-959. PubMed ID: 33179141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
    Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
    Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients.
    Li X; Cai Y
    Aging (Albany NY); 2020 Aug; 12(16):16457-16475. PubMed ID: 32858528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
    Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
    J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
    Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
    Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data mining of immune-related prognostic genes in metastatic melanoma microenvironment.
    Han W; Huang B; Zhao XY; Shen GL
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33169786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
    Tian Q; Gao H; Zhao W; Zhou Y; Yang J
    Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
    Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
    Cervantes J; Rosen A; Dehesa L; Dickinson G; Alonso-Llamazares J
    Actas Dermosifiliogr (Engl Ed); 2019; 110(1):43-49. PubMed ID: 30389125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
    Failmezger H; Muralidhar S; Rullan A; de Andrea CE; Sahai E; Yuan Y
    Cancer Res; 2020 Mar; 80(5):1199-1209. PubMed ID: 31874858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.